采用改良的Sugiura术治疗肝硬化并发门脉高压症患者疗效研究*

目的 探讨采用改良的Sugiura术治疗肝硬化并发门脉高压症患者的疗效及其对门脉血流动力学指标的影响。方法 回忆性分析2013年5月~2015年5月期间我院治疗的56例肝硬化并发门脉高压症患者的临床资料,手术前后采取玻璃管水柱法测量自由门静脉压（FPP）,采用吲哚氰绿15分钟潴留率(ICGR15)检测肝脏储备功能,计算肝脏有效血流（ELBF）,使用B超检测门脉内径、门静脉血流量（PVF）、肝动脉血流（HAF）和肝总血流量（THF）的变化。结果 经过改良的Sugiura术治疗,56例患者手术成功,出现肺部感染和胸腔积液4例,切口感染2例,门静脉血栓形成5例,吻合口狭窄4例,胃瘘1例。经充分引流、营养支持、抗感染、补充白蛋白或输注血浆等对症支持治疗,病情逐步缓解或痊愈;术后FPP水平为（21.3±3.4） cmH₂O,显著低于术前水平【（32.5±5.0）cmH2O,P<0.05】;在术后,56例患者EHBF、THF和PVF水平分别为（0.5±0.1） ml/min、（1481.1±354.0） ml/min和（1046.1±258.0） ml/min,在术后3 m,分别为（0.5±0.3）ml/min、（1574.1±326.0） ml/min和（1131.0±304.1） ml/min,均显著低于术前水平 [分别为（0.7±0.3） ml/min、（1891.0±392.1） ml/min和（1523.1±291.1）ml/min,P<0.05];术后HAF水平为 （435.0±142.1） ml/min,术后3 m时为（443.0±183.1） ml/min,均显著高于术前水平【（368.1±139.1）ml/min,P<0.05】;术后患者ICGR15为（22.7±7.9）%, 显著高于术前的（19.3±5.5）%,差异显著（F=7.327,P<0.05）;手术前后门静脉内径变化差异无统计学意义（P>0.05）;术后1 m和术后3 m,患者血清白蛋白水平大幅升高【分别为（35.2±2.3） g/L和（36.8±1.7） g/L对（31.8±1.7） g/L,P<0.05】;在术后1 m时,患者外周血PLT和WBC计数分别为（144.5±7.2）×10⁹/L和（13.8±0.6）×10⁹/L,在术后3 m时则分别为（98.1±10.6）×10⁹/L和（4.2±0.8）×10⁹/L,均显著高于术前水平【分别为（75.3±6.7）×10⁹/L和（3.4±0.3）×10⁹/L,P<0.05】。结论 采用改良的Sugiura术治疗肝硬化并发门脉高压症患者能够改善肝功能、血细胞和门脉系统血流动力学指标,降低门静脉压力,对防治病情恶化和消化道出血有帮助,其远期疗效还有待观察。     

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes

BackgroundBone marrow fibrosis (BMF), a poor prognostic factor in myelodysplastic syndromes (MDS), in the context of new risk stratifications of MDS has not been fully explored. We examined the relationship between BMF in MDS and survival outcomes, and explored the landscape of somatic gene mutations in the setting of BMF.Patients and MethodsWe retrospectively evaluated 2624 MDS patients for BMF who were divided into 2 groups: grade 0-2 BMF (96%) and severe/grade 3 BMF (4%) based on analysis presented. Commonly MDS tested acquired somatic mutations were also compared between those 2 groups of patients with available next-generation sequencing data.ResultsOnly grade 3 BMF was associated with worse overall survival independent from the Revised International Prognostic Scoring System (IPSS-R) (hazard ratio = 1.6; 95% confidence interval, 1.2-1.9; P < .005). More patients with severe BMF were classified as MDS-EB1 and -EB2 by the World Health Organization 2016 classification, a higher-risk International Prognostic Scoring System score, and a high/very high IPSS-R risk category than patients with grade 0-2 BMF. A complex karyotype, higher bone marrow myeloblasts, lower platelets, and higher rate of elevated lactate dehydrogenase were observed more often in patients with severe BMF. No differences in response to hypomethylating agents or lenalidomide were observed. Among somatic gene mutations tested in MDS, TP53 mutation and SETBP1 were more frequent in patients with grade 3 BMF.ConclusionThe presence of grade 3 BMF is associated with reduced overall survival independent from IPSS-R; however, BMF grade did not affect response to hypomethylating agent or lenalidomide treatment. TP53 and SETBP1 mutations occurred with greater frequency among patients with severe fibrosis.     

Oral-lung microbiome interactions in lung diseases

The proximity and continuity of the oral cavity and the lower respiratory tract allows the oropharyngeal microbiome to be a major determinant of the lung microbiome. In addition, host-pathogen interactions related to the oropharyngeal microbiome or its metabolites could propagate systemic inflammation or modulate host defense mechanisms that could affect other organs, including the lung. There is increasing appreciation of the pathophysiologic significance of the lung microbiome, not only in the classical infection-related diseases, pneumonia, bronchiectasis, and cystic fibrosis, but also in chronic noninfectious lung diseases, such as chronic obstructive pulmonary disease, asthma, and pulmonary fibrosis. In this review, we will explore the relationship of the oral microbiome with lung diseases, such as pneumonia, chronic obstructive pulmonary disease, asthma, and cystic fibrosis.     

Bariatric surgery before,during, and after liver transplantation: a systematic review and meta-analysis

Morbid obesity is considered a relative contraindication for liver transplantation (LTX) because of increased risk of complications. The aim of this study was to investigate the role of bariatric surgery before, during, and after LTX. A systematic review of MEDLINE, EMBASE, CENTRAL, and PubMed databases was performed for studies investigating bariatric surgery in patients before, during, or after LTX. Random-effects meta-analysis of proportions was used to calculate pooled effect estimates. One hundred eighty-seven patients underwent bariatric surgery before LTX (8 studies). After surgery, 82% (95% confidence interval, 62%–97%) of patients were successfully listed for LTX and 70% (95% confidence interval, 40%–93%) successfully received LTX. The 30-day mortality rate was 0%. The graft survival rate after 1 year was 70% (95% confidence interval, 30%–99%). Thirty-day minor and major complications rate was 4% and 1%, respectively. Thirty-two patients underwent bariatric surgery during LTX (2 studies). The 30-day mortality rate after surgery was 0% and 1-year graft survival was 100%. Sixty-four patients underwent bariatric surgery after LTX (9 studies). The 30-day mortality was 0%, but 5 deaths occurred beyond 30 days (7.8%). Bariatric surgery may be safe and feasible as a bridge to LTX for patients who would otherwise be ineligible and post-LTX patients for weight loss.     

实时剪切波弹性成像在拉米夫定治疗乙肝纤维化过程中的疗效评估作用

目的探讨实时剪切波弹性成像在评估拉米夫定治疗乙肝纤维化临床疗效中的作用。方法选取2017年1月～2018年1月我院收治的80例乙肝纤维化患者,根据随机数字法分为对照组和观察组,每组40例。对照组采用常规治疗,观察组在对照组的基础上给予拉米夫定进行治疗,治疗6个月。比较两组治疗前后肝功能、肝纤维化指标,利用实时剪切波弹性成像评估两组治疗前后肝脏弹性模量值及肝穿刺活检情况,并进行比较。结果两组治疗后AST、ALT、TBIL水平均明显低于治疗前,差异有统计学意义(P0.05);观察组治疗后AST、ALT、TBIL水平均明显低于对照组,差异有统计学意义(P0.05);两组治疗后HA、LN、PⅢPN-P、CL-Ⅳ水平及杨氏弹性模量值均显著低于治疗前,差异有统计学意义(P0.05);观察组治疗后HA、LN、PⅢPN-P、CL-Ⅳ水平及杨氏弹性模量值均显著低于对照组,差异有统计学意义(P0.05);与治疗前相比,两组治疗后肝穿刺活检结果均有好转,尤其是汇管区、肝小叶内炎症及肝纤维化改善明显。结论实时剪切波弹性成像作为肝脏硬度定量检测的无创性技术,可用于拉米夫定治疗乙肝纤维化临床疗效评估的重要方法。     

CSF-1R inhibition attenuates ischemia-induced renal injury and fibrosis by reducing Ly6C+ M2-like macrophage infiltration

Acute kidney injury (AKI) to chronic kidney disease (CKD) progression has become a life-threatening disease. However, an effective therapeutic strategy is still needed. The pathophysiology of AKI-to-CKD progression involves chronic inflammation and renal fibrosis driven by macrophage activation, which is physiologically dependent on colony-stimulating factor-1 receptor (CSF-1R) signaling. In this study, we modulated macrophage infiltration through oral administration of the CSF-1R inhibitor GW2580 in an ischemia–reperfusion (I/R)-induced AKI model to evaluate its therapeutic effects on preventing the progression of AKI to CKD. We found that GW2580 induced a significant reduction in the number of macrophages in I/R-injured kidneys and attenuated I/R-induced renal injury and subsequent interstitial fibrosis. By flow cytometry, we observed that the reduced macrophages were primarily Ly6C⁺ inflammatory macrophages in the GW2580-treated kidneys, while there was no significant difference in the number and percentage of Ly6C⁻CX3CR1⁺ macrophages. We further found that these reduced macrophages also demonstrated some characteristics of M2-like macrophages, which have been generally regarded as profibrotic subtypes in chronic inflammation. These results indicate the existence of phenotypic and functional crossover between Ly6C⁺ and M2-like macrophages in I/R kidneys, which induces AKI worsening to CKD. In conclusion, therapeutic GW2580 treatment alleviates acute renal injury and subsequent fibrosis by reducing Ly6C⁺ M2-like macrophage infiltration in ischemia-induced AKI.